Insight Pharma Newsletter

Dear Reader :

We’ve packed this month’s edition of Citeline’s newsletter, developed in alliance with the IPA, with important insights around supply chain resilience, decentralized trials (DCT) and deal activity in India.

The CEO of the Italian API and CDMO specialist Olon talks about why pricing mechanisms need to be adapted to recognize the value of a resilient supply chain, while another piece encapsulates key aspects of the US FDA’s long-awaited draft guidance on DCTs.

We also dissect some of the exciting deal action involving leading Indian firms like Cipla, Dr Reddy’s, Lupin and Ipca.

Anju Ghangurde - Executive Editor (Asia Pacific), Scrip/Pink Sheet
Dr. Shridhar Narayanan - Senior Technical Advisor - Innovation, IPA

8th-global-pharmaceutical-quality-summit-2023

Perspective From Industry Leaders


Olon CEO Says European Systems Must Value Security Of Supply	One Year On: Russia, Ukraine And The Generics Industry
With Olon investing significantly in its production capacity and technical capabilities, CEO Paolo Tubertini believes the API specialist is well-positioned to provide resilience ...	On the anniversary of Russia’s invasion of Ukraine, the generics industry reflects on its contributions to relief efforts as well as the impact that the war has had on the supply chain ...

Licensing & Collaboration Agreements


Asia Deal Watch: Aditum Bio Launches Vitalli To Develop Daewoong Immunology Candidate	'Brands Don’t Die': Cipla Grabs Rights To Novartis’ Galvus In India
In addition, deals involving Lupin/Medisol, Junshi/Dr. Reddy's, Zai Lab/MediLink, Kyowa Kirin/ADVANZ, Ipca/Unichem, Jiangsu Aidea/Kainos ...	Novartis draws up perpetual license agreement with Cipla for its vildagliptin brand in India. Experts weigh in on some deal nuances and whether the DPP-4 ...

Next Gen R&D


EvolveImmune Targets Lymphoma With Novel T-Cell Engagers Harnessing CD2	Eisai Boards Fast Boat To China In HER2-Targeting ADC Deal With Bliss
Emerging Company Profile: The firm’s use of the CD2 co-stimulant in its T cell engager design could significantly boost anti-tumor efficacy while addressing ...	The Japanese drug maker is the second in the space of a month to partner up with a Chinese biotech firm for a HER2-targeting antibody-drug conjugate ...

Clinical Trials


Decentralized Clinical Trials Could Affect Validity Of Non-Inferiority Finding, US FDA Says	Using The Metaverse To Break Down Language Barriers and Improve Diversity In Clinical Trials
Draft guidance notes that data obtained from a decentralized clinical trial may be less precise than that from a site-based trial, creating challenges in ...	Wipro’s life science and medical device lead Gaurica Chacko’s told Medtech Insight about why diversity in healthcare matters to her and what her team ...

Citeline Contact

Poornachandra Tejasvi .K, Senior Director - Emerging Markets, India

Direct: +91 11143155159
Mobile: +91 9945273146
Email: poornachandra.tejasvi@informa.com

Client Services: clientservices@pharmaintel.informa.com

IPA Contact

Direct: +91 022 2610 9281
Email: info@ipa-india.org